<DOC>
	<DOCNO>NCT01403077</DOCNO>
	<brief_summary>This initial evaluation 480 Biomedical Bioresorbable Scaffold System treatment subject de novo native superficial femoral artery lesion .</brief_summary>
	<brief_title>480 Biomedical Bioresorbable Scaffold System Treatment de Novo Superficial Femoral Artery ( SFA ) Lesions</brief_title>
	<detailed_description />
	<mesh_term>Atherosclerosis</mesh_term>
	<criteria>1 . Age &gt; /= 18 year 2 . De novo stenotic lesion ( ) superficial femoral artery locate least 1cm distal femoral bifurcation &gt; 3 cm knee joint 3 . Lifestylelimiting claudication define symptomatic subject Rutherford Becker Category 23 4 . Target lesion native reference vessel diameter 4.6 6.0 mm online QVA ; target lesion native reference vessel diameter le 5.0 mm lesion residual stenosis ≤ 25 % 5 . Lesion length : maximum cover one 100mm scaffold 6 . Target lesion &gt; 50 % stenosis total occlusion 7 . Undisturbed flow foot via least 2 patent infrapopliteal vessel treat side one vessel free &gt; 50 % stenosis ankle joint 8 . Patent common external iliac ; TASC A &amp; B lesion may successfully treat ( &lt; 30 % residual stenosis ) time index procedure 9 . The study patient study patient 's legal representative inform nature study , agree provision provide write informed consent approve Human Research Ethics Committee ( HREC ) respective clinical site 10 . The study patient agree comply required postprocedure followup visit 1 . Previously implant stent ( ) stent graft ( ) target lesion 2 . Previous endovascular treatment target lesion 3 . Femoral access target limb within 30 day study procedure 4 . Target lesion residual stenosis &gt; 30 % predilatation nominally size balloon 5 . Severely calcified lesion determine balloon deformity dilatation nominally size balloon inflate nominal pressure . 6 . Acute embolic complication trifurcation follow predilatation resolve aspiration 7 . Target vessel contains acute thrombus 8 . Aneurysm target vessel 9 . Critical limb ischemia define RutherfordBecker Category 46 10 . Intolerance , allergy adequately premedicated , follow : aspirin , clopidogrel ticlopidine , heparin , scaffold component , contrast agent 11 . Life expectancy le 12 month 12 . Pregnancy breast feeding ( negative pregnancy test within 7 day require female child bear potential ) 13 . Nonatherosclerotic lesion ( e.g . vasculitis Berger 's disease ) 14 . Renal insufficiency ( serum creatinine level &gt; 220 µmol/L , subject dialysis ) 15 . Immunocompromised 16 . Active systemic infection lower limb infection nature 17 . WBC &lt; 3,000 cells/mm3 18 . Myocardial infarction within past 1 month 19 . Stroke within 3 month 20 . Uncontrolled AtrialFibrillation 21 . Currently participate investigational drug another device study . Note : Trials require extend followup product investigational , since become commercially available , consider investigational trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Superficial femoral artery</keyword>
	<keyword>Peripheral arterial disease</keyword>
	<keyword>Atherosclerosis</keyword>
	<keyword>Intermittent Claudication</keyword>
	<keyword>Vascular Diseases</keyword>
	<keyword>Cardiovascular Diseases</keyword>
</DOC>